|
|
|
|
|
|
Sponsors and Collaborators: |
University of Washington National Institute of Allergy and Infectious Diseases (NIAID) |
Information provided by: | University of Washington |
ClinicalTrials.gov Identifier: | NCT00495716 |
The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.
Condition | Intervention | Phase |
Genital Herpes |
Drug: acyclovir |
Phase IV |
Drug Information available for: | Acyclovir Acyclovir sodium |
Study Type: | Interventional |
Study Design: | Other, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission |
Estimated Enrollment: | 500 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | September 2012 |
Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Active Comparator
Episodic Treatment Arm
|
Drug: acyclovir
800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
|
2: Active Comparator
Suppressive Therapy Arm
|
Drug: acyclovir
400 mg orally twice daily for 1 year
|
We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These outcomes will be measured by self-report in a confidential, computer-based assessment. We plan to use data from this trial to model the effect that increasing the proportion of sexually-active HSV-2 infected persons taking suppressive therapy will have on population-level incidence and prevalence of HSV-2.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Karen Mark, MD, MPH | 206-720-4340 | suppression@u.washington.edu |
United States, Washington | |||||
University of Washington Virology Research Clinic | Recruiting | ||||
Seattle, Washington, United States, 98122 | |||||
Contact: Selin Caka 206-720-4340 scaka@u.washington.edu | |||||
Principal Investigator: Karen Mark, MD, MPH |
University of Washington |
National Institute of Allergy and Infectious Diseases (NIAID) |
Principal Investigator: | Karen Mark, MD, MPH | University of Washington |
Responsible Party: | University of Washington ( Karen Mark, MD, MPH / Principal Investigator ) |
Study ID Numbers: | 32545-B, K23 AI071257-01A1 |
First Received: | June 29, 2007 |
Last Updated: | August 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00495716 |
Health Authority: | United States: Institutional Review Board |
|
|
|